Dewys W D, Begg C, Lavin P T, Band P R, Bennett J M, Bertino J R, Cohen M H, Douglass H O, Engstrom P F, Ezdinli E Z, Horton J, Johnson G J, Moertel C G, Oken M M, Perlia C, Rosenbaum C, Silverstein M N, Skeel R T, Sponzo R W, Tormey D C
Am J Med. 1980 Oct;69(4):491-7. doi: 10.1016/s0149-2918(05)80001-3.
The prognostic effect of weight loss prior to chemotherapy was analyzed using data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group. The frequency of weight loss ranged from 31 percent for favorable non-Hodgkin's lymphoma to 87 percent in gastric cancer. Median survival was significantly shorter in nine protocols for the patients with weight loss compared to the patients with no weight loss. Chemotherapy response rates were lower in the patients with weight loss, but only in patients with breast cancer was this difference significant. Decreasing weight was correlated with decreasing performance status except for patients with pancreatic and gastric cancer. Within performance status categories, weight loss was associated with decreased median survival. The frequency of weight loss increased with increasing number of anatomic sites involved with metastases, but within categories of anatomic involvement, weight loss was associated with decreased median survival. These observations emphasize the prognostic effect of weight loss, especially in patients with a favorable performance status or a limited anatomic involvement with tumor.
利用东部肿瘤协作组12项化疗方案中3047例患者的数据，分析了化疗前体重减轻的预后影响。体重减轻的发生率从预后良好的非霍奇金淋巴瘤的31%到胃癌的87%不等。与未体重减轻的患者相比，9项方案中体重减轻的患者中位生存期显著缩短。体重减轻患者的化疗缓解率较低，但仅在乳腺癌患者中这种差异具有显著性。除胰腺癌和胃癌患者外，体重下降与体能状态下降相关。在体能状态类别中，体重减轻与中位生存期缩短相关。体重减轻的发生率随着转移累及的解剖部位数量增加而增加，但在解剖受累类别中，体重减轻与中位生存期缩短相关。这些观察结果强调了体重减轻的预后影响，特别是在体能状态良好或肿瘤解剖受累有限的患者中。
